GYRE
Gyre Therapeutics Inc.
6.80$
-4.0%
vs. previous close
Closing price · As of: Oct 8, 2026
Statements
Balance Sheet
All figures as the change versus the prior period, in percent. Periods without a positive comparison base stay empty.
Tick rows to compare them in a chart (up to 4)
| Line item | 2001 | 2002 | 2003 | 2004 | 2005 | 2006 | 2007 | 2008 | 2009 | 2010 | 2011 | 2012 | 2013 | 2014 | 2015 | 2016 | 2017 | 2018 | 2019 | 2020 | 2021 | 2022 | 2023 | 2024 | 2025 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| – | +122.9% | -12.9% | +22.8% | -51.9% | +190.6% | +21.6% | -0.4% | +224.1% | -17.7% | -1.8% | -26.6% | -23.1% | -23.2% | -37.9% | -45.2% | +3.7% | +216.1% | -21.1% | -3.8% | -41.3% | +52.3% | +37.5% | +7.6% | +32.5% | |
| – | – | – | – | -53.5% | +206.3% | +17.2% | -0.5% | +241.9% | -30.6% | -8.9% | -5.5% | -22.7% | -25.4% | -36.5% | -45.4% | +4.2% | +217.0% | -22.5% | -6.8% | -42.5% | -3.5% | +15.2% | +13.2% | +58.0% | |
| – | – | – | – | -53.2% | +68.0% | +27.9% | -4.1% | +63.9% | +97.7% | -35.3% | -23.3% | -33.7% | +3.6% | -48.4% | -64.7% | +41.0% | +115.7% | -50.8% | +97.5% | +46.1% | -43.2% | +33.1% | -64.7% | +213.8% | |
| – | – | – | – | -53.2% | +118.1% | +60.6% | +1.5% | +25.7% | +92.7% | -8.9% | -35.9% | -26.1% | +16.3% | -69.7% | -47.5% | +90.1% | +270.3% | -36.0% | +3.2% | -41.0% | -46.3% | +33.1% | -20.4% | +96.6% | |
| – | – | – | – | -75.6% | +19,676.0% | -82.0% | -50.6% | +9,634.7% | -99.6% | -74.0% | +533.0% | -79.9% | -49.3% | +248.9% | -93.7% | -22.6% | – | – | -77.9% | -45.1% | +758.9% | +7.8% | +73.1% | +26.7% | |
| – | – | – | – | -59.1% | +314.1% | -19.2% | -28.8% | +1,462.0% | -153.6% | – | – | – | – | – | -42.4% | -72.7% | – | – | – | +89,711.8% | +581.6% | -30.1% | +48.0% | +60.5% | |
| – | – | – | – | – | – | – | – | – | – | – | – | – | – | – | – | – | – | – | – | – | – | – | – | – | |
| – | – | – | – | +5.9% | -7.4% | -7.9% | -57.9% | -9.2% | -10.8% | -11.4% | -12.9% | -15.7% | – | – | – | – | – | – | – | – | -43.1% | -8.5% | +0.4% | +177.2% | |
| – | – | -30.0% | +12,291.9% | +5.1% | -91.4% | +189.4% | -13.1% | +508.1% | -31.7% | -51.0% | -83.7% | -17.6% | -74.1% | +1,207.3% | -42.2% | -60.3% | -43.1% | +507.4% | -37.9% | -22.4% | -14.0% | +718.4% | -73.7% | -11.7% | |
| – | – | – | – | -1.9% | +71.8% | +69.8% | -9.2% | +633.5% | -2.5% | -20.3% | -85.6% | -3.3% | -73.5% | +1,195.7% | -41.8% | -60.2% | -45.1% | +501.9% | -38.4% | -20.4% | -13.6% | +63.8% | -2.6% | -6.3% | |
| – | – | – | – | -29.6% | -24.3% | +54.8% | +51.3% | +3.7% | +18.6% | -27.4% | -31.4% | +0.2% | – | – | -42.5% | -73.8% | – | – | +37.3% | +198.2% | -75.1% | -57.3% | +239.5% | -10.8% | |
| – | – | – | – | -36.7% | +68.9% | +15.8% | -34.7% | -15.0% | +270.3% | -26.1% | -41.1% | -37.0% | -68.8% | +131.9% | -10.9% | -10.8% | +67.1% | +242.9% | +38.6% | +8.2% | -98.1% | +191.0% | -69.6% | +14.8% | |
| – | – | – | – | – | – | -20.6% | +11.2% | +20.2% | +33.1% | +89.8% | +0.9% | -23.5% | -19.0% | -71.2% | -48.9% | +91.5% | +289.8% | -43.0% | +11.3% | -46.0% | +3.5% | -137.2% | – | +67.5% | |
| – | – | – | – | – | – | – | – | – | – | – | – | – | – | – | – | – | – | – | – | – | – | -950.7% | – | – | |
| – | +0.0% | -9.9% | -11.0% | +19.5% | +5,089.6% | +45.1% | +25.1% | +3.9% | +17.6% | +4.9% | +5.8% | +0.5% | +0.4% | -8.2% | +163.8% | +339.6% | +227.5% | +7.1% | +59.8% | +59.8% | +147.0% | -13.0% | +55.4% | +0.9% |
Data as of: October 8, 2026 · Source: fundamental data & SEC filings (annual and quarterly reports, 10-K/10-Q)
Note: pure fact-based analysis, not investment advice and not a solicitation to buy or sell. All figures without guarantee.